<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679560</url>
  </required_header>
  <id_info>
    <org_study_id>782382</org_study_id>
    <secondary_id>D6.715L15J91110</secondary_id>
    <nct_id>NCT02679560</nct_id>
  </id_info>
  <brief_title>Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures</brief_title>
  <official_title>Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures: a Randomized, Active Comparator-controlled, Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Travis W. Gerlach, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-initiated, single-center, randomized, patient blinded, controlled
      trial. The purpose of this study is to compare the effect of a fascia iliaca compartment
      block (FICB) using 0.2% ropivacaine vs. liposomal bupivacaine in patients with femur and/or
      hip fractures admitted to the University of California Davis Medical Center (UCDMC). The
      primary endpoint will be the total opioid requirements during the 72 hour randomization
      period with secondary endpoints including total daily opioid requirements for days 1-3,
      duration of effect and objective pain scores using the numeric rating scale (NRS) during
      their hospital stay.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal
      bupivacaine will result in less total opioid administration during the randomization period
      compared to a fascia iliaca compartment block using 0.2% ropivacaine.

      The long-term goal of this study is to provide pilot information to guide and design larger,
      multicenter trials which will evaluate the utility and cost-effectiveness of long acting
      liposomal bupivacaine as an opioid-sparring analgesic strategy in injured trauma patients.
      Ultimately, it is hoped that this information can improve safe and effective narcotic sparing
      analgesia in the awake, combat casualty, as well as serve as primary steps towards
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid requirements</measure>
    <time_frame>During randomization treatment period</time_frame>
    <description>total opioid requirements during the 72 hour randomization period measured in milligram morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient outcomes</measure>
    <time_frame>During hospital stay</time_frame>
    <description>total daily opioid requirements for days 1-3, duration of effect and objective pain scores using the numeric rating scale (NRS) during their hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Femoral Fractures</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In patients with femur or hip fractures, a fascia iliaca compartment block using liposomal bupivacaine will be administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine HCL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In patients with femur or hip fractures, a fascia iliaca block using using 0.2% ropivacaine will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine</description>
    <arm_group_label>Liposomal Bupivacaine</arm_group_label>
    <other_name>ExparelÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine HCL</intervention_name>
    <description>Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.</description>
    <arm_group_label>Ropivacaine HCL</arm_group_label>
    <other_name>Naropin (trade name)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient's s/p trauma, with confirmed femur and/or hip fractures with a planned
             admission to the hospital

          2. Patient is ambulatory without assistance (e.g. walker, cane, caretaker) prior to
             incident.

        Exclusion Criteria:

          1. &gt;10 hours since presentation to the emergency department

          2. central or peripheral neurologic deficit on presentation

          3. concern or compartment syndrome

          4. associated additional long bone fractures

          5. end stage liver failure

          6. renal failure requiring dialysis

          7. pregnancy or breast feeding

          8. prisoners

          9. coagulopathy with internalized normal ratio (INR) &gt;1.5

         10. use of direct thrombin inhibitors (bivalirudin, argatroban, desirudindabigatran
             etexilate), or direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban)

         11. suspected prolonged intubation within first 12 hours secondary to respiratory failure
             other than peri-procedurally

         12. Adults unable to consent

         13. Pediatric patients &lt;18 years old

         14. Patients exhibiting signs of shock upon admission, heart rate (HR) &gt;120 or systolic
             blood pressure (SBP) &lt;100 mmHg.

         15. History of allergic reaction to local anesthetics

         16. Administration of any other local anesthetic in the 2 hours prior to the study
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Travis Gerlach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California Davis Med Center- Emergency Department</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Travis W. Gerlach, MD</investigator_full_name>
    <investigator_title>Trauma Surgeon; Assistant Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>femur fracture, hip fracture, exparel, liposomal bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

